[go: up one dir, main page]

NO20060665L - N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer - Google Patents

N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer

Info

Publication number
NO20060665L
NO20060665L NO20060665A NO20060665A NO20060665L NO 20060665 L NO20060665 L NO 20060665L NO 20060665 A NO20060665 A NO 20060665A NO 20060665 A NO20060665 A NO 20060665A NO 20060665 L NO20060665 L NO 20060665L
Authority
NO
Norway
Prior art keywords
amidyl
benzimidazolyl
substituted pyrazolyl
kit inhibitors
inhibitors
Prior art date
Application number
NO20060665A
Other languages
English (en)
Inventor
Colin Peter Sambrook Smith
Arlindo L Castelhano
Joshua Bolger
Andrew Philip Crew
Radoslaw Laufer
An-Hu Li
Yingchuan Sun
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of NO20060665L publication Critical patent/NO20060665L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Forbindelser representert ved Formel (I) eller et farmasøytisk akseptabelt salt eller N-oksyd derav er anvendelige ved behandling av kreft.
NO20060665A 2003-08-21 2006-02-10 N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer NO20060665L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49676603P 2003-08-21 2003-08-21
PCT/US2004/026481 WO2005021537A1 (en) 2003-08-21 2004-08-16 N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors

Publications (1)

Publication Number Publication Date
NO20060665L true NO20060665L (no) 2006-05-16

Family

ID=34272512

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060665A NO20060665L (no) 2003-08-21 2006-02-10 N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer

Country Status (19)

Country Link
EP (1) EP1664032B1 (no)
JP (1) JP4795237B2 (no)
KR (1) KR20060115346A (no)
CN (1) CN1839130A (no)
AP (1) AP2006003553A0 (no)
AR (1) AR045389A1 (no)
AT (1) ATE413395T1 (no)
AU (1) AU2004268948A1 (no)
BR (1) BRPI0413785A (no)
CA (1) CA2536151A1 (no)
DE (1) DE602004017623D1 (no)
IL (1) IL173616A0 (no)
IS (1) IS8320A (no)
MX (1) MXPA06002017A (no)
NO (1) NO20060665L (no)
RU (1) RU2006108791A (no)
TW (1) TW200524911A (no)
UA (1) UA84712C2 (no)
WO (1) WO2005021537A1 (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
CA2627598C (en) 2005-11-07 2013-06-25 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
WO2007083904A1 (en) * 2006-01-18 2007-07-26 Lg Household & Health Care Ltd. C-kit activation inhibitor, skin whitening compound and composition for skin whitening containing the same
TW200740776A (en) * 2006-02-06 2007-11-01 Osi Pharm Inc N-phenylbenzotriazolyl c-kit inhibitors
WO2007136103A1 (ja) * 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
WO2008026748A1 (en) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
ES2564797T3 (es) 2009-08-19 2016-03-29 Eisai R&D Management Co., Ltd. Composición farmacéutica con contenido en un derivado de quinolina
RU2560683C2 (ru) 2010-06-25 2015-08-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
JPWO2012121168A1 (ja) * 2011-03-04 2014-07-17 国立大学法人京都大学 キナーゼ阻害剤
MX2013009931A (es) 2011-04-18 2013-10-01 Eisai R&D Man Co Ltd Agentes terapeuticos contra tumores.
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2014098176A1 (ja) 2012-12-21 2014-06-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
WO2014134391A1 (en) 2013-02-28 2014-09-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
RU2658601C2 (ru) 2013-05-14 2018-06-21 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Биомаркер для прогнозирования и оценки чувствительности субъектов с раком эндометрия к соединениям ленватиниба
TW201534597A (zh) 2013-06-20 2015-09-16 Ab Science 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
RS65049B1 (sr) 2015-02-25 2024-02-29 Eisai R&D Man Co Ltd Metoda za suzbijanje gorčine derivata kinolina
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
ES2887426T3 (es) 2015-08-20 2021-12-22 Eisai R&D Man Co Ltd Lenvatinib combinado con etopósido e ifosfamida para su uso en el tratamiento de un tumor
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
GB8610980D0 (en) 1986-05-06 1986-06-11 Ici America Inc Heterocyclic fused tricyclic compounds
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
WO1995021836A1 (en) 1994-02-10 1995-08-17 Pfizer Inc. 5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
US6001866A (en) 1995-10-05 1999-12-14 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5972980A (en) 1995-10-05 1999-10-26 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US6548524B2 (en) 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
EP0846689B1 (en) 1996-12-09 2004-01-14 Pfizer Inc. Benzimidazole compounds
US6414008B1 (en) 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
BR9810456A (pt) 1997-06-27 2001-09-25 Fujisawa Pharmaceutical Co Composto de sulfonamida, método para sua obtenção e seu uso farmacêutico
US5990146A (en) * 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
WO2000006549A1 (en) 1998-07-28 2000-02-10 Nihon Nohyaku Co., Ltd. Fused-heterocycle dicarboxylic diamide derivatives or salts thereof, herbicides and usage thereof
EP1109555A4 (en) 1998-08-31 2001-11-21 Merck & Co Inc Novel angiogenesis inhibitors
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
US6348032B1 (en) * 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
US6329383B1 (en) 1999-01-25 2001-12-11 Pharmacia Ab 2-amino-5-pyrimidine acetic acid compounds
JP2003528802A (ja) 1999-04-02 2003-09-30 ニューロゲン コーポレイション Ｎ−ベンゾイミダゾリルメチル−及びｎ−インドリルメチル−ベンズアミド並びにｃｒｆ調節物質としてのそれらの使用
CO5190696A1 (es) 1999-06-16 2002-08-29 Smithkline Beecham Corp Antagonistas de los receptores il-8
US6534535B1 (en) 1999-08-12 2003-03-18 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
DE19939463A1 (de) 1999-08-20 2001-02-22 Boehringer Ingelheim Pharma Aminocarbonyl-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1085372B1 (en) 1999-09-13 2004-12-22 Eastman Kodak Company Photographic material having improved color reproduction
WO2001021634A1 (en) 1999-09-21 2001-03-29 Lion Bioscience Ag Benzimidazole derivatives and combinatorial libraries thereof
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
WO2001057020A1 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa
AU2001234705A1 (en) 2000-02-01 2001-08-14 Cor Therapeutics, Inc. Indalone and benzimidazolone inhibitors of factor xa
US7087632B2 (en) 2001-03-05 2006-08-08 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
AU2002216314A1 (en) 2000-10-12 2002-04-22 Scott A Henderson Heterocyclic angiogenesis inhibitors
PL366311A1 (en) 2000-12-11 2005-01-24 Tularik Inc. Cxcr3 antagonists
GB0102109D0 (en) 2001-01-26 2001-03-14 Syngenta Ltd Chemical process
CZ20032691A3 (en) * 2001-03-12 2004-04-14 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
WO2002076960A1 (en) 2001-03-22 2002-10-03 Abbott Gmbh & Co. Kg Transition metal mediated process

Also Published As

Publication number Publication date
EP1664032A1 (en) 2006-06-07
IS8320A (is) 2006-02-21
UA84712C2 (en) 2008-11-25
WO2005021537A1 (en) 2005-03-10
RU2006108791A (ru) 2006-07-27
EP1664032B1 (en) 2008-11-05
AR045389A1 (es) 2005-10-26
CA2536151A1 (en) 2005-03-10
TW200524911A (en) 2005-08-01
AP2006003553A0 (en) 2006-04-30
IL173616A0 (en) 2006-07-05
MXPA06002017A (es) 2006-05-31
BRPI0413785A (pt) 2006-11-07
JP4795237B2 (ja) 2011-10-19
DE602004017623D1 (de) 2008-12-18
KR20060115346A (ko) 2006-11-08
AU2004268948A1 (en) 2005-03-10
JP2007502820A (ja) 2007-02-15
CN1839130A (zh) 2006-09-27
ATE413395T1 (de) 2008-11-15

Similar Documents

Publication Publication Date Title
NO20060665L (no) N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer
NO20060664L (no) N-substituerte benzimidazolyl C-kit inhibitorer
NO20060670L (no) N3-substituerte imidazopyridin C-kit inhibitorer
BRPI0411365A (pt) derivados de aminopiridina
EA200501009A1 (ru) Замещённые пирролопиразольные производные в качестве ингибиторов киназы
ATE495155T1 (de) Heterocyclische inhibitoren von mek
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
NO20090443L (no) 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater
NO20061157L (no) 4-pyramidonderivater og deres anvendelse som peptidylpeptidmeinbibitorer
ATE450533T1 (de) Carboxamidderivate
EA200600317A1 (ru) Производные омега-карбоксиарилдифенилмочевины (варианты), фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с их использованием (варианты)
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
NO20081846L (no) Bifenylderivater og deres anvendelse ved behandling av hepatitt C
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
MXPA05012466A (es) Derivados de quinolina como inhibidores de fosfodiesterasa.
NO20060973L (no) Pyridylderivater og deres anvendelse som tempeutiske midler
ATE433981T1 (de) Heterocyclische verbindungen
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
EP2205088A4 (en) NAPHTHALIN-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS
TW200633704A (en) N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library
ECSP055809A (es) Inhibidores 4-oxo-1-(3-fenil sustituido)-1,4-dihidro-1,8-naftiridina-3-carboxamida de la fosfodiesterasa-4
CY1111432T1 (el) Τετραϋδροκινολινες για χρηση ως διαμορφωτες της μιτοτικης κινητικης πρωτεϊνης eg5
ATE476431T1 (de) Piperidin- und azetidinderivate als glyt1- inhibitoren
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application